Cover Image
市場調查報告書

高血壓 : 開發平台分析

Hypertension - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 232783
出版日期 內容資訊 英文 547 Pages
訂單完成後即時交付
價格
Back to Top
高血壓 : 開發平台分析 Hypertension - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 547 Pages
簡介

高血壓指的是動脈的血壓持續上升的狀態。包含體內荷爾蒙、水分、鹽分濃度、腎臟、神經系統或血管狀態等各種因素在內皆會影響血壓。大部分人即使血壓數值高到危險的程度也不會顯露出高血壓的症狀。即使有些人在早期高血壓便有頭部隱隱作痛、頭暈、比一般更容易或流出更多鼻血但典型的患者常是即使高血壓加劇也沒有上述症狀。

本報告提供高血壓的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

高血壓 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • A1M Pharma AB
  • AbbVie Inc.
  • Ache Laboratorios Farmaceuticos S/A
  • Actelion Ltd
  • Afferent Pharmaceuticals, Inc.
  • Allergan Plc
  • Alnylam Pharmaceuticals, Inc.
  • Anacor Pharmaceuticals, Inc.
  • APT Therapeutics, Inc.
  • Arena Pharmaceuticals, Inc.
  • Ascendis Pharma A/S
  • AVEO Pharmaceuticals, Inc.
  • Bayer AG
  • Bial - Portela & Ca, S.A.
  • Bio-inRen
  • BioRestorative Therapies, Inc.
  • Bristol-Myers Squibb Company
  • Cellceutix Corporation
  • Celsion Corporation
  • Celtaxsys, Inc.
  • Chong Kun Dang Pharmaceutical Corp.
  • CJ HealthCare Corp.
  • Complexa, Inc.
  • Conatus Pharmaceuticals Inc.其他

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9406IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypertension - Pipeline Review, H1 2017, provides an overview of the Hypertension (Cardiovascular) pipeline landscape.

Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in body and condition of kidneys, nervous system, or blood vessels. Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels. Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically don't occur until high blood pressure has reached a severe.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypertension - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 7, 35, 35, 31, 89, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 24 and 11 molecules, respectively.

Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertension (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypertension (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypertension (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Hypertension - Overview
  • Hypertension - Therapeutics Development
  • Hypertension - Therapeutics Assessment
  • Hypertension - Companies Involved in Therapeutics Development
  • Hypertension - Drug Profiles
  • Hypertension - Dormant Projects
  • Hypertension - Discontinued Products
  • Hypertension - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Hypertension, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Hypertension - Pipeline by A1M Pharma AB, H1 2017
  • Hypertension - Pipeline by Actelion Ltd, H1 2017
  • Hypertension - Pipeline by Alnylam Pharmaceuticals Inc, H1 2017
  • Hypertension - Pipeline by Anacor Pharmaceuticals Inc, H1 2017
  • Hypertension - Pipeline by AnGes MG Inc, H1 2017
  • Hypertension - Pipeline by Arena Pharmaceuticals Inc, H1 2017
  • Hypertension - Pipeline by Ascendis Pharma A/S, H1 2017
  • Hypertension - Pipeline by Asklepion Pharmaceuticals LLC, H1 2017
  • Hypertension - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
  • Hypertension - Pipeline by Bayer AG, H1 2017
  • Hypertension - Pipeline by Bial - Portela & Ca SA, H1 2017
  • Hypertension - Pipeline by Biolab Farmaceutica Ltda, H1 2017
  • Hypertension - Pipeline by BioRestorative Therapies Inc, H1 2017
  • Hypertension - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017
  • Hypertension - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Hypertension - Pipeline by Camurus AB, H1 2017
  • Hypertension - Pipeline by Capricor Therapeutics Inc, H1 2017
  • Hypertension - Pipeline by Celsion Corp, H1 2017
  • Hypertension - Pipeline by Celtaxsys Inc, H1 2017
  • Hypertension - Pipeline by Chiesi Farmaceutici SpA, H1 2017
  • Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
  • Hypertension - Pipeline by CJ HealthCare Corp, H1 2017
  • Hypertension - Pipeline by Conatus Pharmaceuticals Inc, H1 2017
  • Hypertension - Pipeline by Corion Biotech Srl, H1 2017
  • Hypertension - Pipeline by Cumberland Pharmaceuticals Inc, H1 2017
  • Hypertension - Pipeline by Cytokinetics Inc, H1 2017
  • Hypertension - Pipeline by Daewoong Co Ltd, H1 2017
  • Hypertension - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
  • Hypertension - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Hypertension - Pipeline by DiaMedica Therapeutics Inc, H1 2017
  • Hypertension - Pipeline by Eli Lilly and Company, H1 2017
  • Hypertension - Pipeline by Esperion Therapeutics Inc, H1 2017
  • Hypertension - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Hypertension - Pipeline by Ferring International Center SA, H1 2017
  • Hypertension - Pipeline by Galectin Therapeutics Inc, H1 2017
  • Hypertension - Pipeline by Gemphire Therapeutics Inc, H1 2017
  • Hypertension - Pipeline by Gilead Sciences Inc, H1 2017
  • Hypertension - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Hypertension - Pipeline by H. Lundbeck A/S, H1 2017
  • Hypertension - Pipeline by HanAll Biopharma Co Ltd, H1 2017
  • Hypertension - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
  • Hypertension - Pipeline by HitGen LTD, H1 2017
  • Hypertension - Pipeline by Innopharmax Inc, H1 2017
  • Hypertension - Pipeline by Insmed Inc, H1 2017
  • Hypertension - Pipeline by Insys Therapeutics Inc, H1 2017
  • Hypertension - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
  • Hypertension - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017
  • Hypertension - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017
  • Hypertension - Pipeline by Johnson & Johnson, H1 2017
  • Hypertension - Pipeline by JW Pharmaceutical Corp, H1 2017
  • Hypertension - Pipeline by Kowa Company Ltd, H1 2017
  • Hypertension - Pipeline by Leading BioSciences Inc, H1 2017
  • Hypertension - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017
  • Hypertension - Pipeline by Les Laboratoires Servier SAS, H1 2017
  • Hypertension - Pipeline by LinXis BV, H1 2017
  • Hypertension - Pipeline by Liquidia Technologies Inc, H1 2017
  • Hypertension - Pipeline by Lotus Pharmaceutical Co Ltd, H1 2017
  • Hypertension - Pipeline by MannKind Corp, H1 2017
  • Hypertension - Pipeline by Marina Biotech Inc, H1 2017
  • Hypertension - Pipeline by Merck & Co Inc, H1 2017
  • Hypertension - Pipeline by Mezzion Pharma Co Ltd, H1 2017
  • Hypertension - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
  • Hypertension - Pipeline by Nanoform Cardiovascular Therapeutics Ltd, H1 2017
  • Hypertension - Pipeline by Neurim Pharmaceuticals Ltd, H1 2017
  • Hypertension - Pipeline by Nippon Kayaku Co Ltd, H1 2017
  • Hypertension - Pipeline by Nippon Shinyaku Co Ltd, H1 2017
  • Hypertension - Pipeline by Northern Therapeutics Inc, H1 2017
  • Hypertension - Pipeline by Novartis AG, H1 2017
  • Hypertension - Pipeline by Noxamet Ltd, H1 2017
  • Hypertension - Pipeline by Omeros Corp, H1 2017
  • Hypertension - Pipeline by Peloton Therapeutics Inc, H1 2017
  • Hypertension - Pipeline by Pfizer Inc, H1 2017
  • Hypertension - Pipeline by PhaseBio Pharmaceuticals Inc, H1 2017
  • Hypertension - Pipeline by Pluristem Therapeutics Inc, H1 2017
  • Hypertension - Pipeline by Polyphor Ltd, H1 2017
  • Hypertension - Pipeline by Pulmokine Inc, H1 2017
  • Hypertension - Pipeline by Quantum Genomics SA, H1 2017
  • Hypertension - Pipeline by Reata Pharmaceuticals Inc, H1 2017
  • Hypertension - Pipeline by RedHill Biopharma Ltd, H1 2017
  • Hypertension - Pipeline by Relypsa Inc, H1 2017
  • Hypertension - Pipeline by Renova Therapeutics Inc, H1 2017
  • Hypertension - Pipeline by Respira Therapeutics Inc, H1 2017
  • Hypertension - Pipeline by Reviva Pharmaceuticals Inc, H1 2017
  • Hypertension - Pipeline by rEVO Biologics Inc, H1 2017
  • Hypertension - Pipeline by Rottapharm Biotech Srl, H1 2017
  • Hypertension - Pipeline by Sanofi, H1 2017
  • Hypertension - Pipeline by Savara Inc, H1 2017
  • Hypertension - Pipeline by Serodus ASA, H1 2017
  • Hypertension - Pipeline by Shanghai Pharmaceutical Co Ltd, H1 2017
  • Hypertension - Pipeline by Silence Therapeutics Plc, H1 2017
  • Hypertension - Pipeline by Simcere Pharmaceutical Group, H1 2017
  • Hypertension - Pipeline by SteadyMed Therapeutics Inc, H1 2017
  • Hypertension - Pipeline by Suda Ltd, H1 2017
  • Hypertension - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
  • Hypertension - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
  • Hypertension - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Hypertension - Pipeline by The Medicines Company, H1 2017
  • Hypertension - Pipeline by Theravance Biopharma Inc, H1 2017
  • Hypertension - Pipeline by Toray Industries Inc, H1 2017
  • Hypertension - Pipeline by Torrent Pharmaceuticals Ltd, H1 2017
  • Hypertension - Pipeline by TSH Biopharm Corporation Ltd, H1 2017
  • Hypertension - Pipeline by United Therapeutics Corp, H1 2017
  • Hypertension - Pipeline by Vascular BioSciences, H1 2017
  • Hypertension - Pipeline by Vectura Group Plc, H1 2017
  • Hypertension - Pipeline by VG Life Sciences Inc, H1 2017
  • Hypertension - Pipeline by Vicore Pharma AB, H1 2017
  • Hypertension - Pipeline by Vivus Inc, H1 2017
  • Hypertension - Pipeline by XORTX Pharma Corp, H1 2017
  • Hypertension - Pipeline by XuanZhu Pharma Co Ltd, H1 2017
  • Hypertension - Pipeline by Yuhan Corp, H1 2017
  • Hypertension - Dormant Projects, H1 2017
  • Hypertension - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Hypertension - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Hypertension - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Hypertension - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Hypertension - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Hypertension - Dormant Projects, H1 2017 (Contd..6), H1 2017
  • Hypertension - Dormant Projects, H1 2017 (Contd..7), H1 2017
  • Hypertension - Dormant Projects, H1 2017 (Contd..8), H1 2017
  • Hypertension - Dormant Projects, H1 2017 (Contd..9), H1 2017
  • Hypertension - Dormant Projects, H1 2017 (Contd..10), H1 2017
  • Hypertension - Dormant Projects, H1 2017 (Contd..11), H1 2017
  • Hypertension - Dormant Projects, H1 2017 (Contd..12), H1 2017
  • Hypertension - Dormant Projects, H1 2017 (Contd..13), H1 2017
  • Hypertension - Discontinued Products, H1 2017
  • Hypertension - Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures

  • Number of Products under Development for Hypertension, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top